Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to quetiapine sustained-release in schizophrenia
2004-000913-21Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of quetiapine in schizophrenia, sponsored by AstraZeneca. Primary endpoint: Improved clinical benefit at Week 12. Started Aug 2004; status: completed.
02
Drugs
quetiapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2004-000913-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000913-21.